GRFS vs TAK vs CSL vs BHVN vs OCSL

For growth investors, Oaktree Specialty Lending Corporation (OCSL) is the stronger pick with 60.

9% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 12. 0x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 0x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Carlisle Companies Incorporated's 0. 71x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Carlisle Companies Incorporated (CSL) delivered a total return of +95.

1%, compared to -52. 8% for Grifols, S. A. (GRFS). Over 10 years, the gap is even starker: CSL returned +277. 3% versus GRFS's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Biohaven Ltd. 's 1. 23β — meaning BHVN is approximately 273% more volatile than TAK relative to the S&P 500. On balance sheet safety, Takeda Pharmaceutical Company Limited (TAK) carries a lower debt/equity ratio of 65% versus 5% for Biohaven Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Oaktree Specialty Lending Corporation (OCSL) is pulling ahead at 60.

9% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -45. 8% for Oaktree Specialty Lending Corporation. Over a 3-year CAGR, TAK leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Carlisle Companies Incorporated (CSL) is the more profitable company, earning 14.

8% net margin versus 0. 0% for Biohaven Ltd. — meaning it keeps 14. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OCSL leads at 50. 4% versus 0. 0% for BHVN. At the gross margin level — before operating expenses — OCSL leads at 87. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Carlisle Companies Incorporated's 0. 71x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 17. 2x for Carlisle Companies Incorporated — 16. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHVN: 118. 7% to $21. 29.

In this comparison, OCSL (14.

1% yield), TAK (3. 6% yield), GRFS (2. 6% yield), CSL (1. 2% yield) pay a dividend. BHVN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 3. 6% yield). Both have compounded well over 10 years (TAK: -2. 1%, BHVN: +35. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GRFS (Healthcare) and TAK (Healthcare) and CSL (Industrials) and BHVN (Healthcare) and OCSL (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GRFS is a small-cap deep-value stock; TAK is a mid-cap income-oriented stock; CSL is a mid-cap quality compounder stock; BHVN is a small-cap quality compounder stock; OCSL is a small-cap high-growth stock. GRFS, TAK, CSL, OCSL pay a dividend while BHVN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.